ArticleJournal of cardiovascular translational research2026
Biorefine, a Transcatheter Mitral Annulus Ablation System for the Treatment of Mitral Regurgitation: Pre-Clinical Study in Sheep.
Article in Journal of cardiovascular translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mitral regurgitation (MR) is the most common valvular disease in developed countries. Many patients with functional MR (FMR) are inoperable due to high surgical risk, and effective transcatheter options are limited. Radiofrequency (RF) ablation can contract connective tissue. To assess the feasibility, safety, and efficacy of Biorefine, a novel transcatheter RF ablation system for mitral annulus remodeling without implants, in a preclinical ovine model. Twelve sheep underwent transseptal RF ablation of the posterior mitral annulus under 3D echocardiographic and fluoroscopic guidance. Mitral geometry and coaptation were evaluated acutely (n = 4), at 58 days (n = 4), and 178 days (n = 4). Histology assessed tissue effects. All procedures were complication-free. Eleven of 12 animals showed ≥ 15% annular area reduction (mean 21.8%), ≥ 10% A-P diameter reduction (mean 15%), and 71.9% mean coaptation increase. Histology confirmed localized fibrosis (≤ 3 mm) without off-target injury. Biorefine appears safe, durable, and implant-free for FMR.
Indexed as
Identifiers
41803320What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.